Lewiss on Lifestyle Medicine
The U.S. physical activity guidelines recommend that healthy adults, including elderly, get at least 150 minutes of moderate-intensity aerobic exercise or 75 minutes of high-intensity aerobic exercise weekly.
These guidelines, endorsed by organizations like the American Heart Association, the American College of Lifestyle Medicine and the American Board of Sports Medicine, further recommend twice weekly resistance training, such as muscle strengthening, as well as flexibility and gait training.
I recently caught up with Melissa Leber MD, director of Player Medical

In this interview Ira Zackon, MD, highlights data on bispecific antibody use in patients with multiple myeloma in the community setting as presented at ASH 2025.
Zackon noted that the retrospective observational study included representation of Black Americans and rural populations usually left out of clinical trials, but the real-world research in multiple myeloma remains limited and further analysis will need to be completed.
“It’s certainly important that bispecific antibodies are able to be delivered in the community oncology setting in order to really expand access so patients can get

In this interview Shahzad Raza, MD, discusses a study on the treatment of patients with extramedullary myeloma, as presented at ASH 2025.
“I found this to be a really exciting study. I don't think we can do this type of study in the future easily, because these are very complex and very challenging studies. But I do see a light here for our patients who have this type of bad multiple myeloma, which is difficult to treat, and we can actually offer them this type of therapy,” said Raza, a hematologist-oncologist at Cleveland Clinic Cancer Institute.

In this interview, Ann S. LaCasce, MD, highlights a late-breaking abstract on in vivo CAR T-cell therapy use in multiple myeloma, as presented at ASH 2025.
“[This] has applicability across multiple hematologic malignancies and was really a very exciting new abstract,” LaCasce, associate professor of medicine at Harvard Medical School and director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology, told Healio.
For full Healio coverage of this study and more expert perspectives, click here.

In this interview Shahzad Raza, MD, highlights data on CAR T-cell therapies and the use of bispecifics in earlier lines of multiple myeloma as presented at ASH 2025.
“We have been seeing more and more CAR-Ts that have been employed in earlier lines of the setting. We've been seeing the long-term data about the efficacy of the CAR-T studies. We are seeing the new products of the BCMA CAR-T are in the pipeline,” Raza, a hematologist-oncologist at Cleveland Clinic Cancer Institute, said. “We are also seeing the bispecifics, which are currently being approved in the relapsed, refractory setting,

The CELEBRATE trial evaluated efficacy and safety of a novel subcutaneous glycoprotein IIb/IIIa inhibitor administered upon first medical contact for patients with suspected STEMI.
Read Healio’s in-depth coverage of the CELEBRATE trial.
CELEBRATE included 2,467 patients with presumed symptoms of STEMI for less than 4 hours who were randomly assigned to a single subcutaneous injection of zalunfiban (RUC-4, CeleCor Therapeutics) or placebo at first medical contact — home, ambulance or in hospital.
Risk for the primary efficacy endpoint, which was a hierarchical proportional odds model

The VESALIUS-CV trial evaluated the impact of the PCSK9 inhibitor evolocumab on risk for major adverse cardiovascular events in patients with atherosclerosis and/or diabetes and no prior myocardial infarction or stroke.
Read Healio’s in-depth coverage of the VESALIUS-CV trial.
VESALIUS-CV included 12,257 patients who were randomly assigned evolocumab (Repatha, Amgen) 140 mg or placebo every 2 weeks on top of optimal lipid-lowering therapy.
During a median follow-up of 4.6 years, the addition of evolocumab conferred a 25% relative reduction in risk for the primary endpoint of coronary heart

Calling eye drops “artificial tears” can mislead people into thinking the drops are more sophisticated than they truly are and misguide clinical decisions in dry eye, according to a letter to the editor in The Ocular Surface.
Instead, the term “lubricating drop” should be adopted, as it is “more accurate, more descriptive and more all-encompassing,” Kaleb S. Abbott, OD, MS, FAAO, FOWNS, and Andrew D. Pucker, OD, PhD, FAAO, FSLS, FBCLA, wrote. They believe such a shift would benefit patients and providers alike.
“The use of the term ‘artificial tear’

The FDA approved Nufymco as an interchangeable biosimilar to Lucentis, making it the second approved ranibizumab biosimilar in the U.S. from Formycon and Bioeq, the companies announced in a press release.
Additionally, Zydus Lifesciences Global FZE has entered a strategic partnership with Bioeq. Under the terms of the agreement, Bioeq will be responsible for the development, manufacturing, registration and supply of the biosimilar, while Zydus will control its commercialization in the U.S. market.
Nufymco (ranibizumab-leyk), a VEGF inhibitor, is indicated for the treatment of retinal diseases

The question of whether invasive or noninvasive methods provide the best possible outcomes for patients with neurodegenerative conditions persists for researchers.
A collaboration between Openwater Health, a San Francisco-based medical technology firm, and a Barcelona-based hospital seeks to provide a clear answer by conducting pilot trials with the former’s version of open low-intensity focused ultrasound (LIFU).
Healio spoke with Pablo Villoslada, MD, chair of Hospital del Mar’s department of neurology and director of the neuroscience research program at the hospital’s research institute, to